Sunesis Pharmaceuticals (SNSS) is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. This stock is trading up 5.5% at $2.86 in recent trading.
Today's Range: $2.75-$2.8852-Week Range: $1.01-$3.19 Volume: 213,000 Three-Month Average Volume: 372,878 Shares of SNSS are ripping higher today after he company said it received a $1.5 million milestone payment from Biogen (BIIB) for the advancement of pre-clinical work under its 2011 amended and restated multi-kinase inhibitor collaboration agreement. Under the agreement, Sunesis is also eligible to receive up to $60 million in pre-commercial milestone program payments as well as royalties on sales of future collaboration products. >>22 Biopharma Stocks With Breakout Potential in 2012 From a technical perspective, SNSS is moving sharply higher here back above its 50-day moving average of $2.75 with light volume. This move is has pushed shares of SNSS into breakout territory, since the stock has started to move above some near-term overhead resistance at $2.79. Traders should now look to play the next major breakout trade for SNSS. That trade will trigger once SNSS takes out some past overhead resistance at $3.11 to $3.19 with high-volume. Traders should look for long-biased trades as long as SNSS is trending above $2.79, and then once it sustains a move or close above $3.11 to $3.19 with volume that's near or above 372,878 shares. If we get that action soon, then SNSS will enter new 52-week-high territory, which is bullish price action. Look for the stock to re-test and possibly take out its next significant overhead resistance level at $3.69 if that breakout triggers soon.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV